Pieris/Zydus Partner To Develop Anticalin-Based Therapeutics
Zydus Cadila and Pieris have entered into an alliance for development and commercialisation of multiple novel Anticalin-based protein therapeutics. The collaboration combines Pieris' drug-discovery and early development capabilities with Zydus' expertise in biologics development, regulatory affairs and biologics manufacturing.
Anticalins are recombinantly engineered versions of human lipocalins. To develop Anticalins, Pieris makes discrete changes to those lipocalin amino acid positions responsible for endogenous ligand binding, thereby redirecting specificity away from the natural ligand and to virtually any target of interest. Anticalin and Anticalins are registered trademarks of Pieris.
Under the terms of the agreement, India-based Zydus will take the lead in advancing Anticalin drug candidates through formal preclinical development and into clinical development, undertaking drug development in accordance with ICH guidelines. Zydus has been granted exclusive marketing rights in India and several other emerging markets, while Germany-based Pieris retains exclusive marketing rights in key developed markets. The most advanced programme in the collaboration is PRS-110, an Anticalin specific for c-Met,a target that is becoming increasingly validated across a broad spectrum of tumours. PRS-110, which is a pure antagonist due to its monovalent target engagement, has demonstrated the ability to inhibit both ligand-dependent and -independent c-Met activity in a variety of animal models.